Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Met primary endpoint in Phase III trial for stroke drug Asundexian, representing blockbuster potential. Additionally, the U.S....
— David Herro
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Bayer
No other institutional pitches found for this ticker yet.
More institutional theses from Harris Associates International Equity Strategy